Leerink Partnrs Issues Optimistic Forecast for ALDX Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Equities researchers at Leerink Partnrs upped their Q3 2025 earnings estimates for shares of Aldeyra Therapeutics in a research note issued to investors on Monday, August 11th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their previous estimate of ($0.23). The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.70) EPS.

Other equities research analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 21st. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Monday, May 19th.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ ALDX opened at $5.30 on Thursday. The firm has a market capitalization of $317.47 million, a P/E ratio of -6.24 and a beta of 0.76. Aldeyra Therapeutics has a one year low of $1.14 and a one year high of $7.20. The company’s fifty day moving average is $4.35 and its two-hundred day moving average is $4.25.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05.

Insider Activity at Aldeyra Therapeutics

In related news, insider Stephen Machatha sold 22,073 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $5.15, for a total value of $113,675.95. Following the sale, the insider directly owned 221,799 shares in the company, valued at $1,142,264.85. The trade was a 9.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aldeyra Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ALDX. Kingdon Capital Management L.L.C. purchased a new stake in shares of Aldeyra Therapeutics in the 1st quarter worth about $4,479,000. Raymond James Financial Inc. acquired a new position in Aldeyra Therapeutics in the 4th quarter valued at about $3,628,000. Invesco Ltd. raised its stake in Aldeyra Therapeutics by 1,575.7% in the 1st quarter. Invesco Ltd. now owns 501,137 shares of the biotechnology company’s stock valued at $2,882,000 after purchasing an additional 471,231 shares during the last quarter. AQR Capital Management LLC raised its stake in Aldeyra Therapeutics by 456.3% in the 1st quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company’s stock valued at $2,257,000 after purchasing an additional 321,992 shares during the last quarter. Finally, 683 Capital Management LLC acquired a new position in Aldeyra Therapeutics in the 4th quarter valued at about $1,447,000. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.